{
    "title": "Regeneron expects FDA decision on higher-dose Eylea this year",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12368919/Regeneron-Pharma-beats-profit-estimates-Dupixent-demand.html",
    "date": "2023-08-03",
    "keywords": [
        "drug",
        "eylea",
        "quarter",
        "regeneron",
        "version",
        "khushi",
        "mandowara",
        "decision",
        "eye",
        "fda",
        "pozelimab",
        "approval",
        "partner",
        "blockbuster",
        "market",
        "thursday",
        "food",
        "administration",
        "june",
        "inspection",
        "manufacturer",
        "catalent",
        "basis",
        "midaugust",
        "review",
        "year",
        "line",
        "blood",
        "disease",
        "time",
        "analyst",
        "defense",
        "bayer",
        "dose",
        "dupixent",
        "treatment",
        "decline",
        "profit",
        "share",
        "reporting",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}